Last checked: October 29, 2026. This page explains the rules in plain English. It is not legal advice.
The 30-second answer
BPC-157 is not an FDA-approved drug. Since October 28, 2026, HHS says it won't act against licensed 503A pharmacies that compound one form of it, on a prescription. That is a pause in enforcement, not approval. Research-grade BPC-157 is still a lab reagent only.
Why this is confusing
BPC-157's federal status moved three times in 2026: April 22, July 23 and October 28. Each one made headlines that sounded like "it's legal now."
None of them made BPC-157 an approved drug. Here's what each step really did.
In this article you'll learn:
- The three legal "lanes" BPC-157 can sit in, and which one just opened a crack
- What the October 28 HHS policy allows, and five things it doesn't
- Why a "research use only" label doesn't settle the question on its own
What is BPC-157, in legal terms?
BPC-157 is a peptide: a short chain of 15 amino acids. Picture amino acids as Lego bricks. A peptide is a short chain of bricks; a protein is the whole castle.
Under US law, the same molecule can sit in three different lanes. The lane depends on who makes it, who it's for, and what the seller says about it.
| Lane | What it means | BPC-157 on Oct 29, 2026 |
|---|---|---|
| Approved drug | FDA reviewed and approved a finished product | None exists |
| Compounded drug | A pharmacy mixes it for one patient, on a prescription | Open, narrowly, under the Oct 28 HHS policy |
| Research reagent | Sold for lab tests, not for people | Lawful only with no human-use marketing |
The lanes don't merge. A research vial can't become a pharmacy product by changing hands.
What changed in 2026?
First, four terms you'll see everywhere, in plain English:
- 503A is the section of federal drug law that lets a state-licensed pharmacy or doctor mix a drug for one named patient.
- The 503A bulks list is FDA's list of raw ingredients those pharmacies can use. It fills gaps where no approved drug or official standard exists. Think of it as the approved pantry.
- Category 2 is FDA's red-flag shelf: nominated ingredients it said raise significant safety risks.
- Enforcement discretion means an agency chooses not to enforce a rule under set conditions. It's like a city saying it won't ticket cars on one street while it rewrites the parking rules. The rule itself hasn't changed.
| Date | What happened | What it means |
|---|---|---|
| Sept 2023 | FDA puts BPC-157 in Category 2 | Red flag goes up |
| Apr 22, 2026 | BPC-157 leaves Category 2 after its nominators withdrew | Red flag comes down. Compounding still isn't lawful by itself |
| Jul 23, 2026 | FDA's advisory panel votes 8–6 (1 abstention) to recommend it for the bulks list | Advice only. FDA staff had said no |
| Oct 28, 2026 | HHS issues an interim enforcement-discretion policy for six peptides | A narrow, temporary pharmacy pathway |
| Oct 30, 2026 | Scheduled Federal Register publication; 2-week comment window | The public can weigh in |
Sources for each row are in "The evidence in detail" below. [6]
Did you know? FDA's own scientists recommended against listing BPC-157. The outside advisory panel voted 8–6 in favor anyway. [2]
What this means for you: The 2026 headlines describe a pharmacy pathway, not a green light. For a lab buying research-grade BPC-157, the rules didn't move.
Full breakdown of the vote: The FDA's July 2026 peptide vote, explained
What does the October 28 policy actually allow?
HHS says it doesn't intend to act against a state-licensed pharmacy, federal facility or licensed physician that compounds BPC-157. But only when every condition holds. [6]
The big ones:
- One form only: BPC-157 acetate (the peptide paired with acetate, a common salt form).
- Four routes only: under the skin, into muscle, by mouth or on the skin.
- A patient-specific prescription. No prescription, no coverage.
- A registered source. The raw powder must come from an FDA-registered maker that follows CGMP (FDA's manufacturing quality rules).
- A full COA. That's a certificate of analysis, a lab report card for one batch. It must state the grade "Intended for human drug compounding."
- One ingredient per product. No blends.
- Problems get reported to MedWatch, FDA's safety reporting system.
HHS says it can revisit the policy if a safety signal or quality problem shows up. The full list of conditions is in "The evidence in detail."
What didn't change?
| What changed on Oct 28 | What didn't change |
|---|---|
| 503A pharmacies have a narrow, conditional pathway | BPC-157 is still not FDA-approved. Compounded drugs never are |
| HHS published a detailed COA standard | BPC-157 is still not on the bulks list. That takes a proposed and final rule |
| Six peptides got named forms and routes | 503B outsourcing facilities aren't covered |
| Single-ingredient products can qualify | Blends like BPC-157 + TB-500 can't |
| Research-chemical sales for human use are still unlawful | |
| State law and sport rules still apply |
A 503B outsourcing facility is a larger, FDA-registered compounder that works under factory-style quality rules. The policy names only state-licensed pharmacies, federal facilities and licensed physicians.
The policy runs "until a peptide bulk drug substance is addressed in a final rule." So rulemaking continues. [6]
Did you know? HHS says one goal of the policy is to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers." [6]
Blend research, for context: Wolverine stack research overview
Is it legal to buy research-grade BPC-157?
For genuine lab research, yes, as long as nothing points to human use. Federal law turns on intended use.
Picture a bottle labeled "not for drinking," sold next to cups and a recipe card. Nobody believes the label. FDA reads a peptide storefront the same way.
FDA defines intended use as the seller's "objective intent." It looks at labels, ads and statements. It also weighs "the circumstances surrounding the distribution of the article." [9]
A separate rule covers shipping a new drug only for test-tube or lab-animal research. It sets the label wording, requires checks on the buyer, and requires shipping records kept for 2 years. [10]
Here's what fails the test. On August 24, 2026, FDA wrote to one online peptide seller. It said the products were drugs for human use, "despite statements on your product labeling marketing your products 'for research use only.'" [11]
FDA pointed to study summaries describing disease effects. It also cited bacteriostatic water sold as "the means to prepare an injectable drug."
What this means for you: Research-grade BPC-157 belongs in labs. That means no human-use marketing, no dosing and no injection supplies sold alongside it.
More on this: Are research peptides legal in the US?
Can states be stricter?
Yes. State boards of pharmacy run day-to-day oversight of pharmacies. A federal enforcement policy doesn't override state rules. [12]
Ohio is the clearest example. In December 2025, its Board of Pharmacy addressed peptides "such as BPC-157" in Category 2 or 3. It said they "cannot be compounded because it violates federal and state law." [13]
The same guidance says clinics can't possess drugs labeled "for research purposes only." The Board reports it has summarily suspended more than 30 clinics and med spas since early 2025.
That guidance predates the April and October 2026 federal changes. We haven't surveyed all 50 states, so check your own state board.
Is BPC-157 allowed in sport?
No. WADA, the World Anti-Doping Agency, names BPC-157 under S0, its class for non-approved substances. It's "prohibited at all times." The pharmacy policy changes nothing for tested athletes. [14]
Myth vs. fact
| Myth | Fact |
|---|---|
| "FDA approved BPC-157 in 2026." | No approved drug contains BPC-157. Compounded drugs aren't FDA-approved either. |
| "The July vote made it legal." | The vote was non-binding advice to FDA. |
| "Off Category 2 means pharmacies can make it." | HHS says removal didn't change its 503A status. The Oct 28 policy opened the narrow pathway. |
| "A research-use label makes any sale legal." | FDA judges the whole storefront, not the sticker. |
| "BPC-157 + TB-500 blends are covered now." | The policy covers single-ingredient products only. |
What should a researcher do next?
The 2026 changes raised the paperwork bar for everyone. HHS's COA checklist for compounding makes a useful benchmark for research material too. Before you buy, look for:
- Identity by two independent methods, such as HPLC plus mass spectrometry (a scale that weighs the molecule)
- HPLC purity with the chromatogram, not just a number. HPLC is a race where each molecule crosses the finish line at its own time.
- Endotoxin and bioburden results. Endotoxin is the "smoke" dead bacteria leave behind.
- Residual solvents and elemental impurities
- A named lab and a lot number that matches your vial
How to check one: How to read a certificate of analysis The science behind the compound: BPC-157 research overview
The evidence in detail
BPC-157 status at a glance (Oct 29, 2026)
| Question | Answer | Primary source |
|---|---|---|
| FDA-approved drug? | No | FDA BPC-157 briefing document (Jul 2026) |
| On the 503A bulks list? | No. Listing takes notice-and-comment rulemaking. No proposed rule found as of Oct 29. | FDA 503A bulk drug substances page |
| In Category 2? | No. In Category 2 from Sept 2023 until Apr 22, 2026. HHS says neither placement nor removal changed its 503A status. | HHS policy, Appendix B |
| 503A compounding | Interim enforcement discretion for BPC-157 acetate (SC, IM, oral, topical) when all conditions are met. Publishes Oct 30, 2026; 2-week comments, docket HHS-OASH-2026-0496. | Federal Register doc. 2026-22192; HHS policy PDF |
| 503B outsourcing facilities | Not covered | HHS policy PDF |
| Sold "for research use only" but marketed for people | Unapproved new drug. FDA has issued warning letters on this pattern. | FDA warning letter, Aug 24, 2026 |
| Sport | Prohibited (WADA S0) | WADA Prohibited List |
| State law | Varies by state | Ohio Board of Pharmacy guidance |
Full timeline with sources
| Date | Event | Source |
|---|---|---|
| Sept 2023 | FDA places BPC-157 in 503A Category 2, citing immunogenicity (immune reaction) risk, impurity concerns and limited human safety data. | FDA Category 2 page |
| Apr 15–16, 2026 | FDA files and publishes notice of a July PCAC meeting on seven peptides, including BPC-157 (91 FR 20465, docket FDA-2025-N-6895). | Federal Register, Apr 16, 2026 |
| Apr 22, 2026 | BPC-157 leaves Category 2 after the original nominators withdrew. Removal doesn't by itself make compounding lawful. | HHS policy, Appendix B; FDA Category 2 page ("nominated but withdrawn") |
| Jul 23, 2026 | FDA staff recommend against listing. The PCAC votes 8–6 (1 abstention) to recommend it, for the use FDA reviewed: ulcerative colitis. | FDA PCAC briefing introduction; FDA meeting page (Jul 23 webcast) |
| Oct 28, 2026 | HHS releases its "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," covering BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. | Federal Register public inspection, doc. 2026-22192 |
| Oct 30, 2026 | Scheduled publication. Comment window: 2 weeks, docket HHS-OASH-2026-0496. | Same |
Every condition in the HHS policy, as it applies to BPC-157
- Form and route. BPC-157 acetate with the identity in Appendix B (15 amino acids, H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH, MW 1,419.54 plus acetate), for subcutaneous, intramuscular, oral or topical dosage forms.
- Registered source. The bulk substance comes from an FDA-registered (section 510) manufacturer that complies with CGMP.
- Full COA. Identity by orthogonal (independent) methods, HPLC assay, impurities, residual solvents, elemental impurities, endotoxin and bioburden, with the grade "Intended for human drug compounding."
- A patient-specific prescription.
- Single active ingredient. No BPC-157 blends.
- Reporting. Serious adverse events and quality problems go to FDA MedWatch and the relevant states.
- Labeling. "This is a compounded drug product. Not for resale."
- Oral forms need documentation of adequate oral bioavailability in humans.
The research-shipment rule (21 CFR 312.160)
The rule covers a new drug shipped solely for tests in vitro or in laboratory research animals. It requires the label statement "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans." The shipper must use due diligence that the buyer actually runs such tests, and keep shipment records for 2 years. [10]
Educational content, not legal advice. Laws and enforcement policies change; check the primary sources below and consult a qualified attorney for your situation.
For research use only. Not for human consumption. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
References
- FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, uses evaluated, webcast links, docket FDA-2025-N-6895). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24…
- FDA. PCAC Briefing Document Introduction, July 23–24, 2026 (nominations withdrawn; FDA proposes BPC-157 NOT be listed). www.fda.gov/media/193342/download
- FDA. PCAC Briefing Document, BPC-157-related bulk drug substances. www.fda.gov/media/193343/download
- Federal Register. PCAC notice of meeting, 91 FR 20465, Apr 16, 2026. www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compo…
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register doc. 2026-22192, public inspection Oct 28, 2026; publication Oct 30, 2026). public-inspection.federalregister.gov/2026-22192.pdf (permanent: www.federalregister.gov/d/2026-22192)
- HHS. Policy text with Appendices A and B. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretio…
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A. www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-com…
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-…
- eCFR. 21 CFR 201.128, Meaning of "intended uses." www.ecfr.gov/current/title-21/part-201/section-201.128
- eCFR. 21 CFR 312.160, Drugs for investigational use in laboratory research animals or in vitro tests. www.ecfr.gov/current/title-21/part-312/section-312.160
- FDA. Warning Letter 735063, Aug 24, 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-investigat…
- FDA. Compounding and the FDA: Questions and Answers. www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions…
- Ohio Board of Pharmacy. Ten Common Prescriber Clinic and Medical Spa Violations (updated 12/8/2025). www.pharmacy.ohio.gov/documents/pubs/special/ivtherapy/ten%20common%20…
- WADA. The Prohibited List (S0). www.wada-ama.org/en/prohibited-list
- Secondary, for the vote tally: McDermott Will & Schulte, "Bulk-list bound? PCAC backs majority of peptides," Jul 27, 2026. www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-p… ; ArentFox Schiff, "The (Pep)Tides Turn," Jul 31, 2026. www.afslaw.com/perspectives/alerts/the-peptides-turn-fda-panel-recomme…
- Secondary: Reuters, "US Health Secretary Kennedy opens access to some unapproved peptides," Oct 28, 2026. www.reuters.com/legal/litigation/us-health-department-allow-temporary-…
Research use only
This article is provided for educational and informational purposes and summarizes published laboratory and preclinical research. All ProGrade Peptides products are sold strictly for in-vitro laboratory and research use only (RUO). Nothing here is medical advice, a therapeutic claim, or a protocol for human or animal use. These compounds are not intended to diagnose, treat, cure, or prevent any disease.
Frequently asked questions
It isn't FDA-approved. Since October 28, 2026, HHS says it won't act against 503A pharmacies and physicians that compound BPC-157 acetate under its conditions, with a prescription. Selling it for human use outside that lane is still an unapproved-new-drug violation.
No. No FDA-approved drug product contains BPC-157. Compounded BPC-157 isn't FDA-approved either.
No. The July 23, 2026 vote (8–6, 1 abstention) was a non-binding recommendation. The October 28 policy is an enforcement-discretion statement, not a rule, and BPC-157 isn't on the bulks list.
A state-licensed 503A pharmacy can compound BPC-157 acetate for under-the-skin, muscle, oral or topical use if every condition is met. That includes a patient-specific prescription and a full COA. State law still applies.
Yes. WADA lists BPC-157 under S0, non-approved substances, banned in and out of competition.
Drafted with AI assistance and fact-checked against the cited sources by The ProGrade Research Desk. See our editorial policy and sourcing policy. Spot an error? Report it.
